Platifillin - instructions for use, dose, side effects, contraindications

M-holinoblokator, in comparison with atropine has less influence on peripheral m-holinoretseptory (on action on smooth muscle cells of the organs of the gastrointestinal tract and circular muscle of the iris is 5-10 times weaker than atropine).Blocking m-holinoretseptory, violates the transmission of nerve impulses from postganglionic cholinergic nerves to the effector organs and tissues innervated by them (heart, smooth muscle organs, external secretion glands); suppresses also n-holinoretseptory (much weaker). Holin-blocking effect is more pronounced against a background of increased tone of the parasympathetic part of the autonomic nervous system or the action of m-cholinostimulators. To a lesser extent than atropine, causes tachycardia, especially when used in large doses. Reducing the influence of the vagus nerve, improves the conductance of the heart, increases the excitability of the myocardium, increases the minute volume of blood.

It has a direct myotropic antispasmodic effect, causes the expansion of small vessels of the skin. In high doses, the vasomotor center depresses and blocks sympathetic ganglia, as a result of which vessels dilate and blood pressure decreases (mainly with intravenous administration). Weaker atropine depresses the secretion of endocrine glands; causes a marked decrease in the tone of smooth muscles, the amplitude and frequency of peristaltic contractions of the stomach,duodenal ulcer, small and large intestine, moderate depression of the gallbladder tone (in persons with hyperkinesia of bile ducts); at a hypokinesia - a tonus of a cholic bubble raises to the normal maintenance. It causes relaxation of the smooth muscles of the uterus, bladder and urinary tract; providing spasmolytic action, eliminates pain syndrome. Relaxes the smooth muscles of the bronchi, caused by an increase in the tone of the vagus nerve or holinostimuljatorami, increases the volume of breathing, inhibits the secretion of the bronchial glands; reduces the tone of sphincters.

Indications:

Peptic ulcer of stomach and duodenum, pylorospasm, cholecystitis, cholelithiasis, intestinal colic, renal colic, biliary colic; bronchial asthma (for the prevention of bronchial and laryngospasm).

Contraindications:

Individual sensitivity to the components of the drug.

Elderly and old age, up to 6 years.

Carefully:

Pregnancy; the period of breastfeeding; diseases of the cardiovascular system, in which an increase in the number of heartbeats may be undesirable: atrial fibrillation, tachycardia,chronic heart failure, ischemic heart disease, mitral stenosis, arterial hypertension, acute bleeding; thyrotoxicosis (tachycardia may be worse); increased body temperature (may still increase due to suppression of activity of sweat glands); reflux-esophagitis, hernia of the esophageal opening of the diaphragm, combined with reflux esophagitis (decreased esophageal and gastric motility and relaxation of the lower esophageal sphincter may contribute to slowing the emptying of the stomach and enhancing gastroesophageal reflux through the sphincter with impaired function); diseases of the gastrointestinal tract, accompanied by obstruction: achalasia and stenosis of the pylorus (there may be a decrease in motor and tone, leading to obstruction and delay in stomach contents); atony of the intestine in elderly patients or weakened patients (possible the development of obstruction), paralytic ileus (possible the development of obstruction); diseases with increased intraocular pressure: closed-angle (mydriatic effect, leading to increased intraocular pressure,can cause acute attack) and open-angle glaucoma (mydriatic effect may cause some increase in intraocular pressure, correction of therapy may be required), age over 40 (risk of undiagnosed glaucoma); nonspecific ulcerative colitis (high doses can inhibit intestinal motility, increasing the likelihood of paralytic intestinal obstruction, and possibly the manifestation or exacerbation of such a serious complication as a toxic megacolon); dryness of the oral mucosa (long-term use may cause further intensification of xerostomia); hepatic insufficiency (decreased metabolism) and renal failure (risk of side effects due to reduced excretion); chronic lung diseases, especially in young children and weakened patients (a decrease in bronchial secretion can lead to a thickening of the secret and the formation of congestion in the bronchi); myasthenia gravis (the condition may worsen due to inhibition of the action of acetylcholine); autonomic (autonomic) neuropathy (urinary retention and paralysis of accommodation may be intensified),hypertrophy of the prostate without obstruction of the urinary tract, urinary retention or predisposition to it, or diseases accompanied by obstruction of the urinary tract (including the bladder neck due to prostatic hypertrophy); gestosis (hypertension is possible); brain damage in children (effects from the central nervous system may increase); Down's disease (possibly an unusual dilatation of the pupils and an increase in the number of heartbeats); central paralysis in children (reaction to anticholinergic drugs may be most pronounced).

Patients with diabetes mellitus and people on a diet with a reduced carbohydrate content.

If you have any of these diseases, consult a doctor before taking the drug.

Pregnancy and lactation:

Application during pregnancy and during breastfeeding is recommended only after a careful weighing of the ratio of benefit and risk.

Dosing and Administration:

Inside, before eating. Adults take 1 tablet 2-3 times a day.

Children aged 6-10 years - for ¼ tablets, over 10 years - for ½ tablets 2-3 times a day.

The duration of treatment is determined by the doctor.

Side effects:

The dryness of the oral mucosa, thirst, lowering blood pressure, mydriasis, accommodation paralysis, tachycardia, intestinal atony, dizziness, headache, photophobia, convulsions; retention of urine; acute psychosis (in high doses); atelectasis of the lung.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

Symptoms: paralytic intestinal obstruction, acute urinary retention (in patients with prostatic hyperplasia), paralysis of accommodation, increased intraocular pressure; dryness of mucous membranes of the mouth, nose and throat, difficulty swallowing and speech, mydriasis (or until complete disappearance of the iris), tremors, seizures, hyperthermia, agitation, CNS depression, suppression of the activity of the respiratory and vasomotor centers.

Treatment: gastric lavage; parenteral administration of cholinostimulators and cholinesterase inhibitors of drugs. With hyperthermia - wet wipes,antipyretic drugs; with excitation - intravenous injection of sodium thiopental or rectal - chloral hydrate; with mydriasis - topically, in the form of eye drops phosphacol, physostigmine, pilocarpine. In case of development of an attack of glaucoma immediately, 2 drops of 1% pilocarpine solution are injected into the conjunctival bag immediately, and 0.05% solution (neostigmine methyl sulfate) is injected subcutaneously 3-4 times a day.

Interaction:

Strengthens the sedative and hypnotic effect of phenobarbital, pentobarbital, magnesium sulfate. Other m-holinoblokatory, amantadine, haloperidol, phenothiazine, monoamine oxidase inhibitors, tricyclic antidepressants, and some antihistamines increase the risk of side effects. Antagonism with cholinesterase inhibitors. Morphine intensifies the inhibitory effect on the cardiovascular system; monoamine oxidase inhibitors - a positive chrono- and batmotropic effect; cardiac glycosides - a positive Batmotrope action; quinidine, procainamide m-holin-blocking action. With pain associated with spasms of smooth muscles, the action is intensified by analgesics,sedative and anxiolytic drugs (tranquilizers); with vascular spasms - hypotensive and sedative drugs.

Special instructions:

Patients with diabetes should take into account that one tablet of the drug contains about 0.099 g of carbohydrates (0.008 XE).

Effect on the ability to drive transp. cf. and fur:

During the treatment period it is necessary to refrain from potentially dangerous activities requiring increased attention.

Form release / dosage:Tablets 5 mg.

Packaging:10 tablets per contour cell pack. 1, 2 or 3 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LS-002587

Date of registration:31.01.2012

The owner of the registration certificate:VIFITEH, CJSC VIFITEH, CJSC Russia

Manufacturer: & nbsp

VIFITEH, CJSC Russia

Information update date: & nbsp10.08.2015

Illustrated instructions

Instructions

Platyphylline (Platyphyllin)